PATENT CLAIM ANALYSIS

Application Number: 15774217
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-12
Patent Classification: ["424", "450000"]

Abstract:
A liposomal drug formulation for treating a disease in a patient characterized by overexpression of HIF-1α and/or HIF-2α includes a plurality of liposomes in a pharmaceutically acceptable carrier. The liposomes encapsulate echinomycin and are made from a peglyated phospholipid, a neutral phosphoglyceride, and a sterol. The PEGylated liposomes may be used to treat proliferative diseases, leukemia, cancer, autoimmune diseases and graft-versus-host disease.

Claim (Index 8):
The formulation of  claim 1 , wherein the mass ratio of echinomycin to total lipids is between to 10%.

Metadata:
- Claim Count in Document: 41.0
- Percentile: 93.0
- Lexical Diversity: 1.42857
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13900969', '15221832', '14765620', '11121294', '15301020']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7388997727180469
- 35 USC 102 Novelty (BERT): 0.5283988571681506
- Combined Prediction Score: 0.7178496811630573
- Mean Citation Score: 315.52429999999987
- Max Citation Score: 329.68204
- Similarity Product: 253.43969228020427

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test